Plan a conversation · Myth and fact
It is reasonable to ask both what went wrong in studies and what was never checked. Keep those questions separate so neither gets lost.
The myth to test
Taking a small report count as a complete picture of harm.
The side-effect reporting system at the US medicines agency (FDA) held two reports about ipamorelin through September 30, 2023. FDA classed both as minor. One described watery eyes and a headache after a nasal spray; the other described elbow pain after injections with another peptide. This small count does not tell us that problems are rare.
Feeling sick, throwing up and a swollen belly were common in the bowel-surgery trial, with similar patterns in both groups.
Poor sleep was reported more often with ipamorelin, as was high blood sugar when leaving hospital.
These were adults given ipamorelin into a vein after major surgery; those rates may not apply to other people or ways of giving it.
As of October 1, 2026, FDA’s assessment contained no safety data for ipamorelin injections under the skin.
FDA also raised concern about immune reactions, when the body treats a substance as an invader, because peptides may clump or contain unwanted material.
There is no FDA-reviewed ipamorelin label with information for pregnancy, breastfeeding or children, as of October 1, 2026.
The FDA page about side-effect reports warns that sending in a report does not prove the drug was responsible. How often does a problem happen? These reports cannot answer that.
Patients can report medicine problems without charge through FDA’s MedWatch service.
For a care conversation, bring the product name, your medicines and a clear account of what happened.